Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00848783 · ClinicalTrials.gov registry record · Phase 2
Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers
A Phase 2 study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT00848783: Clinical Trial Phase 2 study, sponsored by NYU Langone Health.
NCT00848783 is a Phase 2 study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00848783, a Phase 2 study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study is to determine whether intraperitoneal (IP) Floxuridine is effective in the patients with advanced stomach or gastro-esophageal junction cancers in the treatment consisting of pre- and post-surgery chemotherapies.
Primary Outcome
This is defined as the patients who did not have recurrence of cancer at 1 year since the start of induction chemotherapy.
Interventions
- DRUG Capecitabine
- DRUG Cisplatin
- DRUG Irinotecan
- PROCEDURE Surgery
- DRUG Floxuridine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2008-05 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
Why NCT00848783 stopped before completion
NCT00848783 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 5 interventions - of which Capecitabine is the first listed.
NCT00848783 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00848783 about?
NCT00848783 is a clinical study titled "Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers". This study is to determine whether intraperitoneal (IP) Floxuridine is effective in the patients with advanced stomach or gastro-esophageal junction cancers in the treatment consisting of pre- and post-surgery chemotherapies.
What is the current status of trial NCT00848783?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2008-05. Estimated completion is 2012-09.
What interventions are being tested in trial NCT00848783?
The interventions under investigation include: Capecitabine (DRUG), Cisplatin (DRUG), Irinotecan (DRUG), Surgery (PROCEDURE), Floxuridine (DRUG).
Who is sponsoring clinical trial NCT00848783?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00848783's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia